Arcutis Names New Chief Financial Officer

Arcutis Announces CFO Transition

Arcutis, a biopharmaceutical company focused on developing treatments for immune-mediated dermatological and gastrointestinal disorders, today announced that its Chief Financial Officer (CFO), Joseph Pigott, will be leaving the company to pursue another opportunity. Mr. Pigott will remain in his role until a successor is appointed and will assist with the transition process.

"We are grateful for Joe's contributions to Arcutis and appreciate his dedication to our mission," said Patrick Segal, President and Chief Executive Officer of Arcutis. "We are committed to ensuring a seamless transition and are already in the process of identifying and evaluating potential candidates for the CFO role."

Mr. Pigott joined Arcutis in 2018 and has played a key role in the company's growth and development, including the successful completion of several financings and the preparation of the company's initial public offering (IPO) in 2020. Under his leadership, the company's financial operations have been strengthened, and the company has made significant progress in building its pipeline of innovative treatments.

Arcutis is a biopharmaceutical company focused on developing treatments for immune-mediated dermatological and gastrointestinal disorders. The company's lead product candidate, tofacitinib, is being developed for the treatment of atopic dermatitis and is currently in Phase 3 clinical trials. Arcutis is also developing a pipeline of other product candidates targeting various immune-mediated disorders, including psoriasis, vitiligo, and inflammatory bowel disease.